1. Adalimumab medium‐term dosing strategy in moderate‐to‐severe hidradenitis suppurativa: integrated results from the phase III randomized placebo‐controlled PIONEER trials. (14th August 2019) Authors: Jemec, G.B.E.; Okun, M.M.; Forman, S.B.; Gulliver, W.P.F.; Prens, E.P.; Mrowietz, U.; Armstrong, A.W.; Geng, Z.; Gu, Y.; Williams, D.A.; Teixeira, H.D.; Kimball, A.B. Journal: British journal of dermatology Issue: Volume 181:Number 5(2019) Page Start: 967 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Adalimumab medium‐term dosing strategy in moderate‐to‐severe hidradenitis suppurativa: integrated results from the phase III randomized placebo‐controlled PIONEER trials. (1st November 2019) Authors: Jemec, G.B.E.; Okun, M.M.; Forman, S.B.; Gulliver, W.P.F.; Prens, E.P.; Mrowietz, U.; Armstrong, A.W.; Geng, Z.; Gu, Y.; Williams, D.A.; Teixeira, H.D.; Kimball, A.B. Journal: British journal of dermatology Issue: Volume 181:Number 5(2019) Page Start: 967 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗